Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
It isnt hyperbole to describe Ozempic and Wegovy as game changers. Over the past decade, GLP-1 agonists have emerged as a viable quick fix to one of the most complex public health problems of recent times
Table 3 Health state, event, drug acquisition and consumable costs used in the analysis, expressed in 2025 Euros ()
Both drugs offer impressive results for weight loss and metabolic health benefits, but their high cost often makes access a challenge
That said, some users still report success with oral BPC-157 for general joint and tendon health, especially when paired with other foundational supplements like glutamine and collagen
In the last section I cover: Lillys business model Lillys competitive advantage Lillys competitors and how they stack up Risks and headwinds Deep dive into the financials My bear/base and bull case valuation models My plan and approach for Eli Lilly and the GLP-1 sector
US$ 23.45
US$ 27.12
US$ 27.64
US$ 28.04
